에피제네틱스 진단 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Epigenetics Diagnostics Market was valued at USD 15.5 billion in 2024 and is poised to register a CAGR of 16.5% from 2025 to 2034. This rapid expansion is largely fueled by the increasing recognition of epigenetic modifications as key contributors to disease development and progression. As research deepens into the role of DNA methylation, histone modifications, and non-coding RNAs in various health conditions, the demand for advanced diagnostic tools is rising exponentially.

In recent years, the widespread adoption of precision medicine, coupled with technological advancements in molecular diagnostics, has significantly accelerated market expansion. The integration of artificial intelligence and machine learning in epigenetic analysis has further enhanced the accuracy and efficiency of diagnostic solutions. Additionally, major pharmaceutical and biotechnology companies are investing heavily in R&D to develop novel epigenetic biomarkers, further propelling the industry forward.

Growing collaborations between research institutions and healthcare providers are also playing a pivotal role in translating scientific discoveries into real-world clinical applications. The increased availability of funding and government initiatives aimed at improving early disease detection and personalized medicine is driving innovation in the field. With the rise in chronic diseases, including cancer and neurodegenerative disorders, the relevance of epigenetic diagnostics continues to grow, positioning the market for sustained expansion over the next decade.

The market is segmented into key product categories, including kits and reagents, instruments, software, and services. In 2024, the global market for these products reached USD 13.4 billion, with the kits and reagents segment dominating at USD 7.6 billion. These diagnostic tools have become indispensable in clinical applications, academic research, and pharmaceutical development. Their growing popularity stems from their user-friendly designs, enhanced assay sensitivity, automation capabilities, and compatibility with cutting-edge platforms like next-generation sequencing (NGS) and polymerase chain reaction (PCR). As the industry moves toward more high-throughput and cost-effective solutions, the demand for reliable and efficient kits continues to escalate.

The application landscape of epigenetics diagnostics is categorized into oncology and non-oncology segments, with oncology commanding a substantial 69% share in 2024. The dominance of this segment is largely attributed to the growing need for early cancer detection and the rising importance of epigenetic biomarkers in diagnosing and treating various malignancies. Changes in DNA methylation patterns, histone modifications, and chromatin remodeling have emerged as crucial indicators of cancer development, enabling more precise and personalized treatment approaches. With the increasing global burden of cancer and continued advancements in biomarker research, the oncology segment remains a major driver of market growth.

The U.S. Epigenetics Diagnostics Market is projected to grow at a CAGR of 16.5% through 2034, reaching USD 24.6 billion by the end of the forecast period. The country remains a frontrunner in this industry, thanks to its robust healthcare infrastructure, extensive research and development initiatives, and early adoption of precision medicine. Government agencies, including the National Institutes of Health (NIH), continue to fund breakthrough research in epigenetics, further accelerating innovation and commercialization. The rising prevalence of chronic diseases, increasing investments from biotech firms, and favorable regulatory policies are further cementing the U.S. as a dominant player in the global epigenetics diagnostics landscape.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cancer and chronic diseases
    • 3.2.1.2 Advancements in epigenomics research and technology
    • 3.2.1.3 Growing demand for non-invasive diagnostics
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of epigenetic diagnostics technologies
    • 3.2.2.2 Limited standardization of testing methods
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021-2034 ($ Mn)

• 5.1 Key trends
• 5.2 Kits and reagents
• 5.3 Instruments
• 5.4 Software and services

Chapter 6 Market Estimates and Forecast, By Application, 2021-2034 ($ Mn)

• 6.1 Key trends
• 6.2 Oncology diagnostics
• 6.3 Non-oncology diagnostics

Chapter 7 Market Estimates and Forecast, By Technology, 2021-2034 ($ Mn)

• 7.1 Key trends
• 7.2 DNA methylation
• 7.3 Histone methylation
• 7.4 MicroRNA modification
• 7.5 Chromatin structures
• 7.6 Other technologies

Chapter 8 Market Estimates and Forecast, By End Use, 2021-2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital and clinics
• 8.3 Pharmaceutical and biotechnology companies
• 8.4 Diagnostic laboratories
• 8.5 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021-2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Abcam
• 10.2 Agilent Technologies
• 10.3 Diagenode
• 10.4 Dovetail Genomics
• 10.5 Element Biosciences
• 10.6 Illumina
• 10.7 Merck
• 10.8 New England Biolabs
• 10.9 PacBio
• 10.10 Promega
• 10.11 QIAGEN
• 10.12 Roche Diagnostics
• 10.13 Thermo Fisher Scientific
• 10.14 Zymo Research